Ferroportin and Erythroid Cells: an Update

Overview

Journal Adv Hematol

Publisher Wiley

Specialty Hematology

Date 2010 Sep 10

PMID 20827391

Citations 3

Authors

Luciano Cianetti

Marco Gabbianelli

Nadia Maria Sposi

Affiliations

Soon will be listed here.

Abstract

In recent years there have been major advances in our knowledge of the regulation of iron metabolism that have had implications for understanding the pathophysiology of some human disorders like beta-thalassemia and other iron overload diseases. However, little is known about the relationship among ineffective erythropoiesis, the role of iron-regulatory genes, and tissue iron distribution in beta-thalassemia. The principal aim of this paper is an update about the role of Ferroportin during human normal and pathological erythroid differentiation. Particular attention will be given to beta-thalassemia and other diseases with iron overload. Recent discoveries indicate that there is a potential for therapeutic intervention in beta-thalassemia by means of manipulating iron metabolism.

Citing Articles

Physiology and pathophysiology of iron in hemoglobin-associated diseases.

Coates T Free Radic Biol Med. 2014; 72:23-40.

PMID: 24726864 PMC: 4940047. DOI: 10.1016/j.freeradbiomed.2014.03.039.

The cardiorenal syndrome in heart failure: cardiac? renal? syndrome?.

Triposkiadis F, Starling R, Boudoulas H, Giamouzis G, Butler J Heart Fail Rev. 2011; 17(3):355-66.

PMID: 22086438 DOI: 10.1007/s10741-011-9291-x.

Crosstalk between Erythropoiesis and Iron Metabolism.

Rivella S, Nemeth E, Miller J Adv Hematol. 2010; 2010.

PMID: 20862206 PMC: 2938435. DOI: 10.1155/2010/317095.

References

Drakesmith H, Schimanski L, Ormerod E, Merryweather-Clarke A, Viprakasit V, Edwards J . Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood. 2005; 106(3):1092-7. DOI: 10.1182/blood-2005-02-0561. View

Schimanski L, Drakesmith H, Talbott C, Horne K, James J, Davis S . Ferroportin: lack of evidence for multimers. Blood Cells Mol Dis. 2007; 40(3):360-9. DOI: 10.1016/j.bcmd.2007.09.007. View

Gabbianelli M, Sargiacomo M, Pelosi E, Testa U, Isacchi G, Peschle C . "Pure" human hematopoietic progenitors: permissive action of basic fibroblast growth factor. Science. 1990; 249(4976):1561-4. DOI: 10.1126/science.2218497. View

Emerson S, Thomas S, Ferrara J, Greenstein J . Developmental regulation of erythropoiesis by hematopoietic growth factors: analysis on populations of BFU-E from bone marrow, peripheral blood, and fetal liver. Blood. 1989; 74(1):49-55. View

Tan J, Mohandas N, Conboy J . High frequency of alternative first exons in erythroid genes suggests a critical role in regulating gene function. Blood. 2005; 107(6):2557-61. PMC: 1895744. DOI: 10.1182/blood-2005-07-2957. View

Lymboussaki A, Pignatti E, Montosi G, Garuti C, Haile D, Pietrangelo A . The role of the iron responsive element in the control of ferroportin1/IREG1/MTP1 gene expression. J Hepatol. 2003; 39(5):710-5. DOI: 10.1016/s0168-8278(03)00408-2. View

Bank A . Regulation of human fetal hemoglobin: new players, new complexities. Blood. 2005; 107(2):435-43. PMC: 1895603. DOI: 10.1182/blood-2005-05-2113. View

Brissot P, Troadec M, Bardou-Jacquet E, Le Lan C, Jouanolle A, Deugnier Y . Current approach to hemochromatosis. Blood Rev. 2008; 22(4):195-210. DOI: 10.1016/j.blre.2008.03.001. View

De Domenico I, Ward D, Nemeth E, Vaughn M, Musci G, Ganz T . The molecular basis of ferroportin-linked hemochromatosis. Proc Natl Acad Sci U S A. 2005; 102(25):8955-60. PMC: 1157058. DOI: 10.1073/pnas.0503804102. View

10.

Liu X, Yang F, Haile D . Functional consequences of ferroportin 1 mutations. Blood Cells Mol Dis. 2005; 35(1):33-46. DOI: 10.1016/j.bcmd.2005.04.005. View

11.

Rice A, Mendez M, Hokanson C, Rees D, Bjorkman P . Investigation of the biophysical and cell biological properties of ferroportin, a multipass integral membrane protein iron exporter. J Mol Biol. 2009; 386(3):717-32. PMC: 2677177. DOI: 10.1016/j.jmb.2008.12.063. View

12.

Zoller H, Koch R, Theurl I, Obrist P, Pietrangelo A, Montosi G . Expression of the duodenal iron transporters divalent-metal transporter 1 and ferroportin 1 in iron deficiency and iron overload. Gastroenterology. 2001; 120(6):1412-9. DOI: 10.1053/gast.2001.24033. View

13.

Rivella S . Ineffective erythropoiesis and thalassemias. Curr Opin Hematol. 2009; 16(3):187-94. PMC: 3703923. DOI: 10.1097/MOH.0b013e32832990a4. View

14.

Tamary H, Shalev H, Perez-Avraham G, Zoldan M, Levi I, Swinkels D . Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood. 2008; 112(13):5241-4. PMC: 2954708. DOI: 10.1182/blood-2008-06-165738. View

15.

Fujita H, Yamamoto M, Yamagami T, Hayashi N, Bishop T, de Verneuil H . Sequential activation of genes for heme pathway enzymes during erythroid differentiation of mouse Friend virus-transformed erythroleukemia cells. Biochim Biophys Acta. 1991; 1090(3):311-6. DOI: 10.1016/0167-4781(91)90195-r. View

16.

Weatherall D . Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet. 2001; 2(4):245-55. DOI: 10.1038/35066048. View

17.

Metcalf D . The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells. Nature. 1989; 339(6219):27-30. DOI: 10.1038/339027a0. View

18.

Lee P, Beutler E . Regulation of hepcidin and iron-overload disease. Annu Rev Pathol. 2009; 4:489-515. DOI: 10.1146/annurev.pathol.4.110807.092205. View

19.

Ogawa K, Sun J, Taketani S, Nakajima O, Nishitani C, Sassa S . Heme mediates derepression of Maf recognition element through direct binding to transcription repressor Bach1. EMBO J. 2001; 20(11):2835-43. PMC: 125477. DOI: 10.1093/emboj/20.11.2835. View

20.

Tanno T, Porayette P, Sripichai O, Noh S, Byrnes C, Bhupatiraju A . Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood. 2009; 114(1):181-6. PMC: 2710947. DOI: 10.1182/blood-2008-12-195503. View